FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1548646397> ?p ?o ?g. }

• W1548646397 endingPage "2768" @default.
• W1548646397 startingPage "2763" @default.
• W1548646397 abstract "To assess the safety of tacrolimus used in combination with oral methotrexate (MTX) to control the signs and symptoms of rheumatoid arthritis (RA) in patients whose disease remains active despite treatment with MTX.This was a multicenter open-label study conducted at 13 US sites. Eighty patients who at baseline had active RA (mean tender/painful joint count 29.4, mean swollen joint count 17.4, mean erythrocyte sedimentation rate 25.1 mm/hour) despite treatment for >/=1 month with a stable, maximally tolerated dosage of oral MTX (</=20 mg/week, median dosage 15 mg/week, range 5-20 mg/week) were enrolled and received 3 mg/day tacrolimus as a single oral dose once per day for 6 months while continuing to receive MTX at the existing stable dosage. All other disease-modifying antirheumatic drugs were discontinued; stable dosage of nonsteroidal antiinflammatory drugs and oral corticosteroids (</=10 mg/day prednisone or its equivalent) were allowed. All 80 patients received at least one dose of the study drug and were included in the primary safety and efficacy analyses. Seventy-five patients had at least one postbaseline efficacy assessment, and 63 patients (78.8%) completed the study. The primary clinical response criterion was the American College of Rheumatology definition of 20% improvement (ACR20) at the end of treatment.Seven patients (12.5%) withdrew from the study because of adverse events possibly or probably related to treatment with tacrolimus, and 4 (5.0%) withdrew due to lack of efficacy. One serious adverse event (pancreatitis) was possibly related to tacrolimus treatment. The mean (+/-SD) creatinine (Cr) level increased from 0.74 +/- 0.16 mg/dl at baseline to 0.81 +/- 0.22 mg/dl (P < 0.001) at the end of treatment. Twenty-three patients (28.8%) had a >/=30% maximum increase in the Cr level from baseline during the study, with the Cr level in 3 patients (3.8%) exceeding the range considered normal for their age and sex. The maximum Cr level during the study was 1.8 mg/dl. The ACR20 clinical response rate at the end of treatment was 52.5% (95% confidence interval 41.6-63.4%).In patients whose active RA persists despite treatment with MTX, tacrolimus in combination with MTX is safe and well-tolerated and provides clinical benefit." @default.
• W1548646397 created "2016-06-24" @default.
• W1548646397 creator A5007789779 @default.
• W1548646397 creator A5014147030 @default.
• W1548646397 creator A5023834873 @default.
• W1548646397 creator A5042930850 @default.
• W1548646397 creator A5054791740 @default.
• W1548646397 creator A5058172323 @default.
• W1548646397 creator A5064949379 @default.
• W1548646397 creator A5073404088 @default.
• W1548646397 creator A5080806600 @default.
• W1548646397 date "2003-10-01" @default.
• W1548646397 modified "2023-10-16" @default.
• W1548646397 title "Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate" @default.
• W1548646397 cites W1562075782 @default.
• W1548646397 cites W1985763670 @default.
• W1548646397 cites W2046622470 @default.
• W1548646397 cites W2071200404 @default.
• W1548646397 cites W2080745602 @default.
• W1548646397 cites W2100753300 @default.
• W1548646397 cites W2123090800 @default.
• W1548646397 cites W2124097898 @default.
• W1548646397 cites W2131658103 @default.
• W1548646397 cites W2142500530 @default.
• W1548646397 cites W2152348310 @default.
• W1548646397 cites W2159106700 @default.
• W1548646397 cites W2326789779 @default.
• W1548646397 doi "https://doi.org/10.1002/art.11257" @default.
• W1548646397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14558080" @default.
• W1548646397 hasPublicationYear "2003" @default.
• W1548646397 type Work @default.
• W1548646397 sameAs 1548646397 @default.
• W1548646397 citedByCount "58" @default.
• W1548646397 countsByYear W15486463972012 @default.
• W1548646397 countsByYear W15486463972013 @default.
• W1548646397 countsByYear W15486463972015 @default.
• W1548646397 countsByYear W15486463972016 @default.
• W1548646397 countsByYear W15486463972017 @default.
• W1548646397 countsByYear W15486463972018 @default.
• W1548646397 countsByYear W15486463972019 @default.
• W1548646397 countsByYear W15486463972020 @default.
• W1548646397 crossrefType "journal-article" @default.
• W1548646397 hasAuthorship W1548646397A5007789779 @default.
• W1548646397 hasAuthorship W1548646397A5014147030 @default.
• W1548646397 hasAuthorship W1548646397A5023834873 @default.
• W1548646397 hasAuthorship W1548646397A5042930850 @default.
• W1548646397 hasAuthorship W1548646397A5054791740 @default.
• W1548646397 hasAuthorship W1548646397A5058172323 @default.
• W1548646397 hasAuthorship W1548646397A5064949379 @default.
• W1548646397 hasAuthorship W1548646397A5073404088 @default.
• W1548646397 hasAuthorship W1548646397A5080806600 @default.
• W1548646397 hasConcept C126322002 @default.
• W1548646397 hasConcept C141071460 @default.
• W1548646397 hasConcept C197934379 @default.
• W1548646397 hasConcept C198451711 @default.
• W1548646397 hasConcept C2777575956 @default.
• W1548646397 hasConcept C2778143017 @default.
• W1548646397 hasConcept C2778720950 @default.
• W1548646397 hasConcept C2779384505 @default.
• W1548646397 hasConcept C2781059491 @default.
• W1548646397 hasConcept C2909675724 @default.
• W1548646397 hasConcept C2911091166 @default.
• W1548646397 hasConcept C71924100 @default.
• W1548646397 hasConcept C90924648 @default.
• W1548646397 hasConceptScore W1548646397C126322002 @default.
• W1548646397 hasConceptScore W1548646397C141071460 @default.
• W1548646397 hasConceptScore W1548646397C197934379 @default.
• W1548646397 hasConceptScore W1548646397C198451711 @default.
• W1548646397 hasConceptScore W1548646397C2777575956 @default.
• W1548646397 hasConceptScore W1548646397C2778143017 @default.
• W1548646397 hasConceptScore W1548646397C2778720950 @default.
• W1548646397 hasConceptScore W1548646397C2779384505 @default.
• W1548646397 hasConceptScore W1548646397C2781059491 @default.
• W1548646397 hasConceptScore W1548646397C2909675724 @default.
• W1548646397 hasConceptScore W1548646397C2911091166 @default.
• W1548646397 hasConceptScore W1548646397C71924100 @default.
• W1548646397 hasConceptScore W1548646397C90924648 @default.
• W1548646397 hasIssue "10" @default.
• W1548646397 hasLocation W15486463971 @default.
• W1548646397 hasLocation W15486463972 @default.
• W1548646397 hasOpenAccess W1548646397 @default.
• W1548646397 hasPrimaryLocation W15486463971 @default.
• W1548646397 hasRelatedWork W1569392312 @default.
• W1548646397 hasRelatedWork W2003921494 @default.
• W1548646397 hasRelatedWork W2090686119 @default.
• W1548646397 hasRelatedWork W2111150739 @default.
• W1548646397 hasRelatedWork W2338328911 @default.
• W1548646397 hasRelatedWork W2347424991 @default.
• W1548646397 hasRelatedWork W3150855330 @default.
• W1548646397 hasRelatedWork W3207196874 @default.
• W1548646397 hasRelatedWork W4200557508 @default.
• W1548646397 hasRelatedWork W4247645528 @default.
• W1548646397 hasVolume "48" @default.
• W1548646397 isParatext "false" @default.
• W1548646397 isRetracted "false" @default.
• W1548646397 magId "1548646397" @default.
• W1548646397 workType "article" @default.